Head-to-head evidence
adalimumab vs SFA-002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195676 · Phase 3 · completed
Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.
Next expected readout: December 2027 · NCT05503875 (registry estimate)
SFA-002
Developed by SFA Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · SFA-002's landscape